Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.76 |
| ▸ | INSR | P06213 | 14/20 | 0.76 |
| ▸ | IGF1R | P08069 | 14/20 | 0.76 |
| ▸ | EGFR | P00533 | 6/20 | 0.69 |
| ▸ | MET | P08581 | 3/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.69 |
| ▸ | JAK2 | O60674 | 2/20 | 0.69 |
| ▸ | STK10 | O94804 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | FYN | P06241 | 2/20 | 0.69 |
| ▸ | FES | P07332 | 2/20 | 0.69 |
| ▸ | CSF1R | P07333 | 2/20 | 0.69 |
| ▸ | YES1 | P07947 | 2/20 | 0.69 |
| ▸ | LYN | P07948 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30141659 | 1.00 | ALK (0.76) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25014437 | 0.96 | ALK (0.74) | ALKINSRIGF1REGFRMET | |
| SCHEMBL30141609 | 0.96 | ALK (0.74) | ALKINSRIGF1REGFRMET | |
| SCHEMBL24326970 | 0.93 | ALK (0.72) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25014054 | 0.92 | ALK (0.71) | ALKINSRIGF1REGFRMET | |
| SCHEMBL30141642 | 0.92 | ALK (0.71) | ALKINSRIGF1REGFRMET | |
| SCHEMBL24326982 | 0.92 | ALK (0.74) | ALKINSRIGF1REGFRMET | |
| SCHEMBL30425857 | 0.91 | ALK (0.70) | ALKINSRIGF1REGFRMET | |
| SCHEMBL26655424 | 0.91 | ALK (0.70) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25014047 | 0.89 | ALK (0.70) | ALKINSRIGF1REGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-29 | — | — | US | claimed |
| EP-4371983-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2024-05-22 | — | — | EP | claimed |
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-29 | — | — | US | disclosed |
| EP-4371983-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117794914-A | Pyrimidine-2, 4-diamine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-03-29 | — | — | CN | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2023287130-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | 한국화학연구원 | 2023-01-19 | — | — | WO | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALK 13/4885INSR 82/4885IGF1R 7/4885 |
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | WEE2, WEE1, ERBB2 | ALK 1560/4885INSR 2235/4885IGF1R 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.